Obesity and GLP-1 Drugs

The FDA has approved the first oral GLP‑1 prescription for obesity — an oral Wegovy (semaglutide) pill — which in clinical trials produced roughly 13–17% average total body weight loss over about 15 months versus about 2–3% for placebo, comparable to injectable Wegovy. Novo Nordisk says the pill will be made in North Carolina, is expected to be commercially available in early January with starter pricing reported near $149/month, must be taken on an empty stomach with a 30‑minute wait before eating due to an absorption enhancer, and commonly causes nausea and diarrhea.